Investigational drug · Phase 2
LAD191
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hidradenitis Suppurativa.
Phase 2Last checked: Nov 19, 2026Latest source record: May 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "LAD191"
First trial start
2025
Nov 5, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LAD191", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hidradenitis Suppurativa
Approved drugs for the same conditions: Hidradenitis suppurativa · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "LAD191" as an intervention, largest first.
- A Study of LAD191 in Adults With Hidradenitis SuppurativaPivotal-lookingRecruiting
Almirall, S.A.Industry
NCT07151937 · 200 participants (planned) · Start Nov 5, 2025 · Primary completion May 25, 2027
Drug: LAD191; Adalimumab · For: Hidradenitis Suppurativa
Sites: Manises, Spain
Almirall, S.A.Industry
NCT06488209 · 69 participants · Start Jul 29, 2022 · Primary completion Apr 3, 2025
Drug: LAD191 · For: Healthy Volunteers; Autoimmune Disease
Sites: Miami, Florida; Philadelphia, Pennsylvania; San Antonio, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Hidradenitis Suppurativa
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- OlatorepatideHS-20094Phase 38 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes
- SonelokimabPhase 37 trials
MoonLake Immunotherapeutics AG · Hidradenitis Suppurativa, Arthritis, Psoriatic
- brivekimigSAR442970Phase 25 trials
Sanofi · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus
- MAS825ArumakimigPhase 24 trials
Novartis · NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations, Still´s Disease, VEXAS Syndrome
- EltrekibartLY3041658Phase 22 trials
Eli Lilly · Ulcerative Colitis, Ulcerative Colitis Chronic, Hidradenitis Suppurativa
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.